Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.

Hartz AM, Miller DS, Bauer B.

Mol Pharmacol. 2010 May;77(5):715-23. doi: 10.1124/mol.109.061754. Epub 2010 Jan 25.

2.
3.

Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling.

Park R, Kook SY, Park JC, Mook-Jung I.

Cell Death Dis. 2014 Jun 26;5:e1299. doi: 10.1038/cddis.2014.258.

4.
5.

Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A.

Neuropharmacology. 2014 Apr;79:668-78. doi: 10.1016/j.neuropharm.2014.01.023. Epub 2014 Jan 24.

6.

P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.

Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM.

J Clin Invest. 2005 Nov;115(11):3285-90. Epub 2005 Oct 20.

7.

ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.

Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue LF, Stanimirovic D, Zhang W.

J Neurosci. 2009 Apr 29;29(17):5463-75. doi: 10.1523/JNEUROSCI.5103-08.2009.

8.

Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice.

Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN, Kihara T, Asada-Utsugi M, Kinoshita A, Takahashi R.

Brain Res. 2009 Oct 19;1294:202-10. doi: 10.1016/j.brainres.2009.07.078. Epub 2009 Jul 30.

PMID:
19646974
9.

A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV.

J Clin Invest. 2012 Apr;122(4):1377-92. doi: 10.1172/JCI58642. Epub 2012 Mar 12.

10.

Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Deane R, Zlokovic BV.

Curr Alzheimer Res. 2007 Apr;4(2):191-7. Review.

PMID:
17430246
11.

Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease.

Xiong H, Callaghan D, Wodzinska J, Xu J, Premyslova M, Liu QY, Connelly J, Zhang W.

Neurosci Bull. 2011 Aug;27(4):221-32. doi: 10.1007/s12264-011-1015-7.

PMID:
21788993
12.

α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction.

Chen Y, Peng Y, Che P, Gannon M, Liu Y, Li L, Bu G, van Groen T, Jiao K, Wang Q.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17296-301. doi: 10.1073/pnas.1409513111. Epub 2014 Nov 17.

13.

P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations.

Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD.

Neurobiol Aging. 2015 Sep;36(9):2475-82. doi: 10.1016/j.neurobiolaging.2015.05.020. Epub 2015 Jun 6.

PMID:
26159621
14.

Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance.

Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, Deane RJ, Zhong E, Parisi M, Ciszewski J, Kasper RT, Deane R.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14771-6. doi: 10.1073/pnas.1302212110. Epub 2013 Aug 19.

15.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

16.

Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.

Wu G, Miller RA, Connolly B, Marcus J, Renger J, Savage MJ.

Neurodegener Dis. 2014;14(2):53-66. doi: 10.1159/000353634. Epub 2013 Oct 23.

PMID:
24158021
17.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
18.

MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.

Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S.

Brain Pathol. 2007 Oct;17(4):347-53. Epub 2007 Jul 4.

PMID:
17610523
19.

Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow.

Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, Pautler RG, Taffet GE, Zheng H.

Mol Neurodegener. 2014 Aug 9;9:28. doi: 10.1186/1750-1326-9-28.

20.

Interactions between amyloid-β and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease.

Chuang JY, Lee CW, Shih YH, Yang T, Yu L, Kuo YM.

PLoS One. 2012;7(3):e33120. doi: 10.1371/journal.pone.0033120. Epub 2012 Mar 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk